Bulk Anti-Human CD11a (38) Antibody

Product Specifications

Background

Anti-CD11a may be used to study a variety of biological phenomena related to the function of cell adhesion molecules. This antibody may be used to study transplantation rejections and to assist in characterizing lymphomas and leukemias.

CAS Number

9007-83-4

Specifications

Anti-CD11a In Vivo Antibody - Low Endotoxin (38) recognizes Human CD11a. Anti-Human CD11a (Anti-LFA-1a) recognizes the (Mr 175 kDa) a chain of the leukocyte function associated antigen-1 (LFA-1). The leukocyte integrin LFA-1 is a member of a family of heterodimeric receptors that mediate divalent cation-dependent cellular adhesion reactions. LFA-1A binds to domain 1 of an intercellular adhesion molecule (ICAM) on target tissues.

Product Name Alternative

LFA-1 alpha, LFA-1A, Integrin alpha-L, ITGAL

UniProt

P20701

Host

Mouse

Species Reactivity

Human

Target

CD11a

Isotype

IgG2a

Clone

Applications

Flow Cytometry, Western Blot, IHC (Frozen), Immunofluorescence, Immunoprecipitation

Purification Method

This monoclonal antibody was purified using Protein A

Concentration

1.0 - 5.0 mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100mL ICH3002-100mL ICH3003-100mL

Shipping Conditions

Blue ice

Storage Conditions

Anti-CD11a In Vivo Antibody - Low Endotoxin (38) is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Formulation

0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.

Antigen Distribution

The CD11a antigen is present on most leukocytes and plays a vital role in cellular immune responses which require adhesion. Lymphocyte activation via the T-cell antigen receptor (TCR) up-regulates LFA-1 function. The absence of LFA-1A or B may induce the disease state known as leukocyte adhesion deficiency (LAD). Tumor cells which do not express LFA-1 may have avoided cellular immune-responses such as those carried out by natural killer cells (NK).